OCTOVA: Paclitaxel, olaparib and cediranib in platinum-resistant ovarian cancer
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this clinical trial if you:
- have ovarian cancer, fallopian tube cancer or primary peritoneal cancer and your cancer got worse within 12 months of having platinum chemotherapy
- have at least one area of cancer that can be measured on a scan
- have a tissue sample (a biopsy) available for the study team to do some tests on
- have a good overall level of fitness
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
This trial is looking to find better treatments for women with ovarian cancer that has come back. The trial is looking to find out if the drugs olaparib and cediranib are safe and work better than the standard chemotherapy drug paclitaxel.
The drugs involved in this trial are:
- Paclitaxel – the known drug. This is a chemotherapy drug given as a weekly intravenous (into the veins) infusion.
- Olaparib – the drug being tested. This is a type of drug known as a PARP inhibitor, a targeted treatment. It's a tablet taken twice daily.
- Cediranib – the drug being tested. This is type of drug known as a VEGF inhibitor. It's a tablet taken once daily.
If you take part in this study, you'll be randomised (placed into a treatment group by a computer) into one of three treatment groups:
- Paclitaxel only
- Olaparib only
- Olaparib and cediranib together
